RevOpsis and Kemwell partner to boost biologic development
License out/in
Preview
Source: Pharmaceutical Technology
Kemwell will produce RO-104 for treating neovascular age-related macular degeneration. Credit: Jo Panuwat D/ Shutterstock.
RevOpsis Therapeutics has entered a strategic manufacturing collaboration with contract development and manufacturing organisation Kemwell Biopharma to accelerate the development of new multispecific biologics.
The deal speeds up the development of RevOpsis’ lead candidate, RO-104, a tri-specific biologic aimed at treating neovascular age-related macular degeneration (nAMD).
The alliance will harness the manufacturing prowess of Kemwell alongside RevOpsis’ Rev-Mod platform, to streamline the development process for multispecific biologics.
RevOpsis will gain access to a biologics development solution, enabling a swift transition from pre-clinical works to first-in-human clinical trials to advance the development of RO-104 and the broader platform.
See Also:Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Merging the plug-and-play multispecific biologics platform of RevOpsis with the deep biologics development and manufacturing expertise of Kemwell will aid the partnership to quicken the discovery of therapeutics and advance them to investigational new drug (IND) submission.
The partnership is designed to link preclinical works, process development and clinical production to lower the complexity and timelines typically associated with handling early Good Manufacturing Practices (GMP) processes.
“Kemwell’s exemplary track record in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies to patients efficiently. This collaboration aligns with our mission to develop groundbreaking treatments expeditiously, and bring our innovation to patients worldwide.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.